Genexine
5
50M
5
0.21
2
- Areas of investment
Summary
Genexine is the famous Corporate Investor, which was founded in 1999. The company was established in Asia in South Korea. The leading representative office of defined Corporate Investor is situated in the Seongnam.
For fund there is no match between the country of its foundation and the country of its the most frequent investments - China. Moreover, a startup needs to be at the age of 1 and less years to get the investment from the fund. Among the most successful fund investment fields, there are Biotechnology, Pharmaceutical. Among the most popular portfolio startups of the fund, we may highlight I-Mab Biopharma.
The usual cause for the fund is to invest in rounds with 3 partakers. Despite the Genexine, startups are often financed by C-Bridge Capital. The meaningful sponsors for the fund in investment in the same round are Tasly Pharmaceutical, C-Bridge Capital. In the next rounds fund is usually obtained by Tasly Pharmaceutical, Tally Capital, Hony Capital.
The top activity for fund was in 2017. The fund is constantly included in less than 2 investment rounds annually. Deals in the range of more than 100 millions dollars are the general things for fund.
Investments analytics
Analytics
- Total investments
- 5
- Lead investments
- 0
- Exits
- 2
- Rounds per year
- 0.21
- Investments by industry
- Biotechnology (5)
- Product Research (2)
- Pharmaceutical (1)
- Life Science (1)
- Genetics (1) Show 3 more
- Investments by region
-
- China (1)
- South Korea (3)
- United States (1)
- Peak activity year
- 2017
- Number of Minotaurs
- 1
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 13
- Group Appearance index
- 0.80
- Strategy success index
- 0.38
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| GI Innovation | 12 Apr 2021 | Biotechnology | Early Stage Venture | 52M | Seoul, Seoul-t'ukpyolsi, South Korea |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.